Goldman Sachs
WX

Goldman Sachs’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

Goldman Sachs’s Portfolio WX Stock Details WX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-7,600
Closed -$328K – 7612
2015
Q3 		$328K Buy
+7,600
New +$321K ﹤0.01% 5525

Other funds holding WX

Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
CCS
Crosspoint Capital Strategies Orinda, California $50.4M AUM 15.37% 1-Year Est. Return

Goldman Sachs's WX Position: Q4 2015 in Review

Goldman Sachs sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q4 2015, closing a stake of 73,980 shares — an estimated $3.2M sold.

Goldman Sachs first reported a position in WX in Q3 2013 and held it in 8 quarters. The position peaked at $3.2M in Q3 2015. 2 funds tracked by Wall St. Rank hold WX as of Q4 2015.

  • Goldman Sachs reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q4 2015 after selling out during the quarter.
  • Goldman Sachs sold 73,980 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q4 2015, an estimated $3.2M.
  • Goldman Sachs first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q3 2013 and held it in 8 quarters.
  • Goldman Sachs's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $3.2M in Q3 2015.
  • 2 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q4 2015.

Based on Goldman Sachs's 13F filing for Q4 2015, filed 16 Feb 2016.